Atherosclerotic disease in non-insulin-dependent diabetes mellitus: role of abnormal lipids and the place for lipid-altering therapies.
Orloff
D G
DG
Division of Metabolic and Endocrine Drug Products, Food and Drug Administration, Rockville, MD USA.
Blazing
M A
MA
O'Connor
C M
CM
D001161:Arteriosclerosis / Q000097:blood / Q000188:drug therapy / Q000209:etiology*; D001786:Blood Glucose / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D004359:Drug Therapy, Combination; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000150:complications / Q000188:drug therapy; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008055:Lipids / Q000097:blood*; D012307:Risk Factors
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D008055:Lipids